Labcorp, or Laboratory Corporation of America Holdings (NYSE:LH), recently declared its
Q1 and Q2 2024 earnings calls, which beat quarter estimates due to strong testing demand, lifting its
2024 EPS view following the
Q1 reports. Interestingly, it has consistently shown rising relative strength though it is still shy of a key threshold. Recent highlight include Labcorp's winning bid for select assets of Invitae and the acquisition of select assets of BioReference Health's diagnostics business. Consequently, American Century Companies Inc. now holds $152.60 million in Labcorp. More so, the company's
CEO compensation package could be under review, and the company proceeded with selling shares, including the EVP trading $2.77M company stock. Collaborations are also on the rise, with Labcorp and Hawthorne Effect teaming up to bring clinical trials directly to local communities. The company has likewise announced several other initiatives, such as a new test for assessing
Peeeclampisia Risk and the acceleration of Alzheimer's disease diagnosis. However, despite the impressive returns, Labcorp cut its 2023 profit forecast after its clinical development unit spin-off and saw a 20% drop in COVID test sales in Q4.
Laboratory Corporation of America Holdings LH News Analytics from Tue, 23 Jun 2009 07:00:00 GMT to Sat, 14 Sep 2024 08:31:52 GMT -
Rating 4
- Innovation 2
- Information 6
- Rumor -4
